Key result
Darusentan treatment in aged rats increased sodium and potassium excretion (P<0.05), reduced cortical gene expression of alphaENaC and alpha(1)-Na(+), K(+)-ATPase, and increased aldosterone levels.
Why the study?
Does ETA receptor blockade with darusentan increase sodium and potassium excretion in aging male Wistar rats?
Population
Male Wistar rats (aged 3 and 24 months)
Comparison
Darusentan 20 mg/kg/d orally for 4 weeks vs Placebo
Design
Preclinical
Follow-up
4 weeks
Authors
Loading...
Hypothesis-generating for endothelin-sodium links in aging; no implications for human therapy.
Does ETA receptor blockade with darusentan increase sodium and potassium excretion in aging male Wistar rats?
p-value: p=<0.05
ETA receptor blockade with darusentan increases sodium and potassium excretion in aged rats, suggesting a pathogenetic link between aging, endothelin, and sodium sensitivity.
Traupe et al. (2006) studied Aging-related changes in sodium excretion. Darusentan vs. Placebo was evaluated on Ion excretion (sodium, chloride, potassium) (p=<0.05). Darusentan treatment in aged rats increased sodium and potassium excretion (P<0.05), reduced cortical gene expression of alphaENaC and alpha(1)-Na(+), K(+)-ATPase, and increased aldosterone levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: